The single pregnancy predicting model of 1 minute Apgar score less than 7 after preterm birth: A retrospective study.
Autorzy:
Lin XS; Department of Obstetrics, Women's Hospital, Zhejiang University, School of Medicine, Hangzhou, China. Peng XY; Department of Obstetrics, Women's Hospital, Zhejiang University, School of Medicine, Hangzhou, China. Yang MM; Department of Obstetrics, Women's Hospital, Zhejiang University, School of Medicine, Hangzhou, China. Ning LL; Hangzhou Fuyang Women and Children Hospital, Hangzhou, China. ShaoYW; Changxing Women and Children's Hospital, Huzhou, China. Jiang Y; Department of Obstetrics, Women's Hospital, Zhejiang University, School of Medicine, Hangzhou, China. Feng SW; Department of Obstetrics, Women's Hospital, Zhejiang University, School of Medicine, Hangzhou, China. Luo Q; Department of Obstetrics, Women's Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2022 Dec 22; Vol. 17 (12), pp. e0279385. Date of Electronic Publication: 2022 Dec 22 (Print Publication: 2022).
Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes.
Autorzy:
Lu J; Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Yu R; Translational Medicine Research Institute, Geneseeq Technology Inc, Toronto, ON, Canada. Liu R; Translational Medicine Research Institute, Geneseeq Technology Inc, Toronto, ON, Canada. Liang X; Department of Pathology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. Sun J; Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Zhang H; Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Wu H; Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Zhang Z; Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. ShaoYW; Nanjing Geneseeq Technology Inc, Nanjing, Canada.; School of Public Health, Nanjing Medical University, Nanjing, China. Guo J; Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Liang Z; Department of Pathology, Molecular Pathology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2021 Feb; Vol. 10 (3), pp. 933-943. Date of Electronic Publication: 2020 Dec 22.
Effect of different rehabilitation training timelines to prevent shoulder dysfunction among postoperative breast cancer patients: study protocol for a randomized controlled trial.
Autorzy:
ShaoYW; The Second Clinical College of Wuhan University, Wuhan, Hubei, China.; Department of Rehabilitation Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. Shu Q; Department of Rehabilitation Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. Xu D; Department of Rehabilitation Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. Teng H; Department of Rehabilitation Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. Wu GS; Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. Hou JX; Department of Thyroid and Breast Surgery, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. Tian J; Department of Rehabilitation Medicine, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. .
Pokaż więcej
Źródło:
Trials [Trials] 2021 Jan 06; Vol. 22 (1), pp. 16. Date of Electronic Publication: 2021 Jan 06.
Association of circulating tumor DNA from the cerebrospinal fluid with high-risk CNS involvement in patients with diffuse large B-cell lymphoma.
Autorzy:
Wang X; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Gao Y; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Shan C; Department of Medical Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China. Lai M; Department of Medical Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China. He H; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Bai B; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Ping L; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Rong Q; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Ai R; Department of Medical Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China. Wen L; Department of Medical Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China. Zhou Z; Department of Medical Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China. Yu R; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Ontario, Canada. Ou Q; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Ontario, Canada. Wu X; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Ontario, Canada. Wang X; Nanjing Geneseeq Technology Inc., Nanjing, China. ShaoYW; Nanjing Geneseeq Technology Inc., Nanjing, China.; School of Public Health, Nanjing Medical University, Nanjing, China. Cai L; Department of Medical Oncology, Guangdong Sanjiu Brain Hospital, Guangzhou, China. Huang H; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Quantitative characterization of tumor cell-free DNA shortening.
Autorzy:
Guo J; Department of Thoracic Surgery, Chinese PLA General Hospital, 28 Fuxing Rd, Beijing, 100853, China. Ma K; Department of Thoracic Surgery, Chinese PLA General Hospital, 28 Fuxing Rd, Beijing, 100853, China. Bao H; Translational Medicine Research Institution, Geneseeq Technology Inc., Suite 200, South Tower, MaRS Discovery District, 101 College St, Toronto, ON, M5G 1L7, Canada. Ma X; Translational Medicine Research Institution, Geneseeq Technology Inc., Suite 200, South Tower, MaRS Discovery District, 101 College St, Toronto, ON, M5G 1L7, Canada. Xu Y; Translational Medicine Research Institution, Geneseeq Technology Inc., Suite 200, South Tower, MaRS Discovery District, 101 College St, Toronto, ON, M5G 1L7, Canada. Wu X; Translational Medicine Research Institution, Geneseeq Technology Inc., Suite 200, South Tower, MaRS Discovery District, 101 College St, Toronto, ON, M5G 1L7, Canada. ShaoYW; Translational Medicine Research Institution, Geneseeq Technology Inc., Suite 200, South Tower, MaRS Discovery District, 101 College St, Toronto, ON, M5G 1L7, Canada.; Department of Public Health, Nanjing Medical University, 140 Hanzhong Rd, Nanjing, 210029, Jiangsu Province, China. Jiang M; Oncology Center, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, 16 Jichang Rd, Guangzhou, 510405, Guangdong Province, China. . Huang J; Department of Oncology, Xiangya Hospital, Central South University, 87 Xiangya Rd, Changsha, 410008, Hunan Province, China. .
Pokaż więcej
Źródło:
BMC genomics [BMC Genomics] 2020 Jul 10; Vol. 21 (1), pp. 473. Date of Electronic Publication: 2020 Jul 10.
Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling.
Autorzy:
Zou Z; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China. Ou Q; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON, Canada. Ren Y; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China. Lv Q; Yixing Tumor Hospital, Yixing, China. Qin L; Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, China. Zhao L; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China. Su S; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China. Wu X; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON, Canada. Bao H; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON, Canada. Wang A; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON, Canada. Zhu D; Nanjing Geneseeq Technology Inc., Nanjing, China. Wang X; Nanjing Geneseeq Technology Inc., Nanjing, China. ShaoYW; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON, Canada.; School of Public Health, Nanjing Medical University, Nanjing, China. Liu B; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China.
Pokaż więcej
Źródło:
Pigment cell & melanoma research [Pigment Cell Melanoma Res] 2020 Jul; Vol. 33 (4), pp. 601-611. Date of Electronic Publication: 2020 Jan 27.
YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.
Autorzy:
Dai H; Tumor Research and Therapy Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China. ShaoYW; Nanjing Geneseeq Technology Inc, Nanjing, China.; School of Public Health, Nanjing Medical University, Nanjing, China. Tong X; Translational Medicine Research Institute, Geneseeq Technology Inc, Toronto, Ontario, Canada. Wu X; Translational Medicine Research Institute, Geneseeq Technology Inc, Toronto, Ontario, Canada. Pang J; Nanjing Geneseeq Technology Inc, Nanjing, China. Feng A; Tumor Research and Therapy Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China. Yang Z; Tumor Research and Therapy Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2020 Mar; Vol. 9 (5), pp. 1628-1637. Date of Electronic Publication: 2019 Dec 18.
Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
Autorzy:
Chen Z; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. Sun T; Translational Medicine Research Institute, Geneseeq Technology Inc, Toronto, Ontario, Canada. Yang Z; The Second Clinical Medical College of Zhejiang, Chinese Medical University, Hangzhou, China. Zheng Y; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. Yu R; Translational Medicine Research Institute, Geneseeq Technology Inc, Toronto, Ontario, Canada. Wu X; Translational Medicine Research Institute, Geneseeq Technology Inc, Toronto, Ontario, Canada. Yan J; Nanjing Geneseeq Technology Inc., Nanjing, China. ShaoYW; Nanjing Geneseeq Technology Inc., Nanjing, China.; School of Public Health, Nanjing Medical University, Nanjing, China. Shao X; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. Cao W; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China. Wang X; Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Combinatorial assessment of ctDNA release and mutational burden predicts anti-PD(L)1 therapy outcome in nonsmall-cell lung cancer.
Autorzy:
Fang W; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. Ma Y; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. Yin JC; Nanjing Geneseeq Technology Inc., Nanjing, China. Zhou H; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. Wang F; Nanjing Geneseeq Technology Inc., Nanjing, China. Bao H; Department of Medical, Geneseeq Technology Inc., Toronto, Ontario, Canada. Wang A; Department of Medical, Geneseeq Technology Inc., Toronto, Ontario, Canada. Wu X; Department of Medical, Geneseeq Technology Inc., Toronto, Ontario, Canada. Hong S; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. Yang Y; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. Huang Y; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. Zhao H; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China. ShaoYW; Nanjing Geneseeq Technology Inc., Nanjing, China.; School of Public Health, Nanjing Medical University, Nanjing, China. Zhang L; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer.
Autorzy:
Xu J; Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Key Laboratory of Liaoning Breast Cancer Research, Shenyang, Liaoning 110042, P.R. China. Bao H; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON M5G 1L7, Canada. Wu X; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON M5G 1L7, Canada. Wang X; Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu 210032, P.R. China. ShaoYW; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON M5G 1L7, Canada.; School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China. Sun T; Department of Medical Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Key Laboratory of Liaoning Breast Cancer Research, Shenyang, Liaoning 110042, P.R. China.
Pokaż więcej
Źródło:
Oncology letters [Oncol Lett] 2019 Jul; Vol. 18 (1), pp. 449-455. Date of Electronic Publication: 2019 Apr 30.
Molecular genetic characterization reveals linear tumor evolution in a pulmonary sarcomatoid carcinomas patient with a novel PHF20-NTRK1 fusion: a case report.
Autorzy:
Ge J; Department of Thoracic Surgery, Yinzhou People's Hospital, Ningbo, Zhejiang, China. Yao B; Department of Radiotherapy and Chemotherapy, Yinzhou People's Hospital, 251 Baizhang E Rd, Jiangdong Qu, Ningbo, 315000, Zhejiang, China. Huang J; Department of Radiotherapy and Chemotherapy, Yinzhou People's Hospital, 251 Baizhang E Rd, Jiangdong Qu, Ningbo, 315000, Zhejiang, China. Wu X; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON, Canada. Bao H; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON, Canada. Ou Q; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON, Canada. ShaoYW; Nanjing Geneseeq Technology Inc., Floor 18, Building B, 3-1 Xinjinhu Road, Pukou District, Nanjing, 210032, JS, China. yang.shao@geneseeq.com.; School of Public Health, Nanjing Medical University, Nanjing, JS, China. yang.shao@geneseeq.com. Chen J; Department of Radiotherapy and Chemotherapy, Yinzhou People's Hospital, 251 Baizhang E Rd, Jiangdong Qu, Ningbo, 315000, Zhejiang, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2019 Jun 17; Vol. 19 (1), pp. 592. Date of Electronic Publication: 2019 Jun 17.
Transformation to small cell lung cancer and activation of KRAS during long-term erlotinib maintenance in a patient with non-small cell lung cancer: A case report.
Autorzy:
Gu Y; Department of Chemotherapy and Radiation Sickness, Peking University 3rd Hospital, Beijing 100191, P.R. China. Zhu X; Department of Pathology, Peking University 3rd Hospital, Beijing 100191, P.R. China. Cao B; Department of Chemotherapy and Radiation Sickness, Peking University 3rd Hospital, Beijing 100191, P.R. China. Wu X; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON M5G 1L7, Canada. Tong X; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON M5G 1L7, Canada. ShaoYW; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, ON M5G 1L7, Canada.; School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China. Liang L; Department of Chemotherapy and Radiation Sickness, Peking University 3rd Hospital, Beijing 100191, P.R. China.
Pokaż więcej
Źródło:
Oncology letters [Oncol Lett] 2019 Jun; Vol. 17 (6), pp. 5219-5223. Date of Electronic Publication: 2019 Mar 28.
Genomic profiling of synchronous triple primary tumors of the lung, thyroid and kidney in a young female patient: A case report.
Autorzy:
Peng L; Department of Thoracic Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China. Zeng Z; Department of Thoracic Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China. Teng X; Department of Pathology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China. Chen Z; Department of Pathology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China. Lin L; Department of PET/CT, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China. Bao H; Translational Medicine Research Institute, Geenseeq Technology Inc., Toronto, ON M5G1L7, Canada. ShaoYW; Translational Medicine Research Institute, Geenseeq Technology Inc., Toronto, ON M5G1L7, Canada. Wang Y; Department of Thoracic Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China. Dong Y; Department of Respiratory Disease, YinZhou Second Hospital, Ningbo, Zhejiang 315040, P.R. China. Zhao Q; Department of Thoracic Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China.
Pokaż więcej
Źródło:
Oncology letters [Oncol Lett] 2018 Nov; Vol. 16 (5), pp. 6089-6094. Date of Electronic Publication: 2018 Aug 20.
Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
Autorzy:
Kang J; Guangdong Cardiovascular Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Chen HJ; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Zhang XC; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Su J; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Zhou Q; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Tu HY; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Wang Z; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Wang BC; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Zhong WZ; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Yang XN; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Chen ZH; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Ding Y; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Ontario, Canada. Wu X; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Ontario, Canada. Wang M; BioScience Department, Dizal (Jiangsu) Pharmaceutical Co. Ltd, Shanghai, China. Fu JG; BioScience Department, Dizal (Jiangsu) Pharmaceutical Co. Ltd, Shanghai, China. Yang Z; BioScience Department, Dizal (Jiangsu) Pharmaceutical Co. Ltd, Shanghai, China. Zhang X; Medical Department, Nanjing Geneseeq Technology Inc., Nanjing, China. ShaoYW; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Ontario, Canada.; School of Public Health, Nanjing Medical University, Nanjing, China. Wu YL; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.; Medical Research Center, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China. Yang JJ; Guangdong Cardiovascular Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.; Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2018 Sep; Vol. 9 (9), pp. 1093-1103. Date of Electronic Publication: 2018 Jul 06.
Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma.
Autorzy:
Lu H; Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (lung and esophagus), Zhejiang Cancer Hospital, NO.1 East Banshan Road, Gongshu District, Hangzhou, 310022, People's Republic of China.; Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, People's Republic of China. Yang S; Department of Pathology, Zhejiang Cancer Hospital, Hangzhou, 310022, People's Republic of China. Zhu H; Department of Pathology, Zhejiang Cancer Hospital, Hangzhou, 310022, People's Republic of China. Tong X; Translational Medicine Research Institute, Geneseeq Technology Inc, Suite 300, MaRS Centre, South Tower, 101 College Street, Toronto, ON, M5G 1L7, Canada. Xie F; Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, People's Republic of China. Qin J; Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, People's Republic of China. Han N; Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, People's Republic of China. Wu X; Translational Medicine Research Institute, Geneseeq Technology Inc, Suite 300, MaRS Centre, South Tower, 101 College Street, Toronto, ON, M5G 1L7, Canada. Fan Y; Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (lung and esophagus), Zhejiang Cancer Hospital, NO.1 East Banshan Road, Gongshu District, Hangzhou, 310022, People's Republic of China.; Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, People's Republic of China. ShaoYW; Translational Medicine Research Institute, Geneseeq Technology Inc, Suite 300, MaRS Centre, South Tower, 101 College Street, Toronto, ON, M5G 1L7, Canada. yang.shao@geneseeq.com. Mao W; Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (lung and esophagus), Zhejiang Cancer Hospital, NO.1 East Banshan Road, Gongshu District, Hangzhou, 310022, People's Republic of China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2018 Mar 05; Vol. 18 (1), pp. 251. Date of Electronic Publication: 2018 Mar 05.
Cell-Free DNA Provides a Good Representation of the Tumor Genome Despite Its Biased Fragmentation Patterns.
Autorzy:
Ma X; Geneseeq Technology Inc., Suite 300, MaRS Centre, South Tower, Toronto, Ontario, Canada. Zhu L; Jiangsu Cancer Hospital, 42 Baiziting, Xuanwu, Nanjing, Jiangsu, China. Wu X; Geneseeq Technology Inc., Suite 300, MaRS Centre, South Tower, Toronto, Ontario, Canada. Bao H; Geneseeq Technology Inc., Suite 300, MaRS Centre, South Tower, Toronto, Ontario, Canada. Wang X; Nanjing Shihe Jiyin Biotechnology Inc., 17th Floor, Building B, Sino-Danish Life Science Park, 3 Xinjinhu Road, Nanjing, Jiangsu, China. Chang Z; Nanjing Shihe Jiyin Biotechnology Inc., 17th Floor, Building B, Sino-Danish Life Science Park, 3 Xinjinhu Road, Nanjing, Jiangsu, China. ShaoYW; Geneseeq Technology Inc., Suite 300, MaRS Centre, South Tower, Toronto, Ontario, Canada. Wang Z; Department of Medical Oncology, The First Affiliated Hospital of Soochow University, Cang Lang Qu, Suzhou, Jiangsu, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2017 Jan 03; Vol. 12 (1), pp. e0169231. Date of Electronic Publication: 2017 Jan 03 (Print Publication: 2017).
Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state.
Autorzy:
Shimoda M; Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada. Principe S; Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada. Jackson HW; Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada. Luga V; Centre for Systems Biology, Samuel Lunenfeld Research Institute, Toronto, M5G 1X5, Canada. Fang H; Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada. Molyneux SD; Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada. ShaoYW; Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada. Aiken A; Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada. Waterhouse PD; Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada. Karamboulas C; Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada. Hess FM; Institute of Pharmacology and Toxicology, RWTH Aachen University, 52074 Aachen, Germany. Ohtsuka T; Keio University, School of Medicine, Tokyo 160-8582, Japan. Okada Y; Keio University, School of Medicine, Tokyo 160-8582, Japan. Ailles L; Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada. Ludwig A; Institute of Pharmacology and Toxicology, RWTH Aachen University, 52074 Aachen, Germany. Wrana JL; Centre for Systems Biology, Samuel Lunenfeld Research Institute, Toronto, M5G 1X5, Canada. Kislinger T; Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada. Khokha R; Ontario Cancer Institute, University Health Network, Toronto, M5G 2M9, Canada.
Pokaż więcej
Źródło:
Nature cell biology [Nat Cell Biol] 2014 Sep; Vol. 16 (9), pp. 889-901. Date of Electronic Publication: 2014 Aug 24.
Human somatic cell mutagenesis creates genetically tractable sarcomas.
Autorzy:
Molyneux SD; Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada. Waterhouse PD; Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada. Shelton D; Digital-biology Center, Bio-Rad Laboratories, Pleasanton, California, USA. ShaoYW; Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada. Watling CM; Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada. Tang QL; Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada. Harris IS; Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada. Dickson BC; Department of Pathology and Division of Orthopaedic Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada. Tharmapalan P; Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada. Sandve GK; Department of Informatics, University of Oslo, Blindern, Oslo, Norway. Zhang X; Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada. Bailey SD; Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada. Berman H; Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada. Wunder JS; Department of Pathology and Division of Orthopaedic Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada. Izsvák Z; Max-Delbruck-Center for Molecular Medicine, Berlin, Germany. Lupien M; Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada. Mak TW; Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada. Khokha R; Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada.
Pokaż więcej
Źródło:
Nature genetics [Nat Genet] 2014 Sep; Vol. 46 (9), pp. 964-72. Date of Electronic Publication: 2014 Aug 17.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
